| Title |
Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study
|
|---|---|
| Published in |
PharmacoEconomics, November 2014
|
| DOI | 10.1007/s40273-014-0229-8 |
| Pubmed ID | |
| Authors |
Bohdan Nosyk, Viviane Lima, Guillaume Colley, Benita Yip, Robert S. Hogg, Julio S. G. Montaner |
| Abstract |
Through delayed HIV disease progression, highly active antiretroviral therapy (HAART) may reduce direct medical costs, thus at least partially offsetting therapy costs. Recent findings regarding the secondary preventive benefits of HAART necessitate careful consideration of funding allocations for HIV/AIDS care. Our objective is to estimate non-HAART direct medical costs at different levels of disease progression and over time in British Columbia, Canada. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Canada | 1 | 3% |
| Unknown | 37 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 36% |
| Student > Master | 12 | 31% |
| Other | 3 | 8% |
| Student > Ph. D. Student | 3 | 8% |
| Librarian | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 3 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 33% |
| Economics, Econometrics and Finance | 5 | 13% |
| Social Sciences | 4 | 10% |
| Nursing and Health Professions | 3 | 8% |
| Agricultural and Biological Sciences | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 8 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2014.
All research outputs
#20,242,779
of 22,770,070 outputs
Outputs from PharmacoEconomics
#1,748
of 1,816 outputs
Outputs of similar age
#303,341
of 362,492 outputs
Outputs of similar age from PharmacoEconomics
#24
of 26 outputs
Altmetric has tracked 22,770,070 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,816 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 362,492 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.